Frank Richard G, Conti Rena M, Goldman Howard H
Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA.
Milbank Q. 2005;83(2):271-98. doi: 10.1111/j.1468-0009.2005.00347.x.
The pace of innovation in psychotropic drugs has been rapid over the past 15 years. There also have been unprecedented increases in spending on prescription drugs generally and psychotropic medications specifically. Psychotropic medications are playing a more central role in treatment. They also are receiving close scrutiny from health insurers, state budget makers, and ordinary citizens. Public policy actions regarding prescription drugs have the potential to significantly affect clinical care for mental disorders, the costs of this care to individuals and society at large, and the prospects for future scientific advances. This article outlines the policy issues related to psychotropic drugs with respect to their role in determining access to mental health treatment and the cost and quality of mental health care.
在过去15年里，精神药物的创新步伐一直很快。总体而言，处方药支出，尤其是精神药物支出也出现了前所未有的增长。精神药物在治疗中发挥着越来越核心的作用。它们也受到了健康保险公司、州预算制定者和普通公民的密切关注。有关处方药的公共政策行动有可能显著影响精神障碍的临床护理、个人和整个社会为此护理承担的成本，以及未来科学进步的前景。本文概述了与精神药物相关的政策问题，涉及它们在决定获得心理健康治疗的机会以及心理健康护理的成本和质量方面所起的作用。
